JNNP:肌萎缩侧索硬化症胸椎型变异的分型

2021-10-22 MedSci原创 MedSci原创

胸椎管变异型肌萎缩侧索硬化症(T-ALS)是一种罕见的亚型,仅影响3%的肌萎缩侧索硬化症(ALS)患者。为了更好地理解这种变异,旨在描述T-ALS的典型特征,包括临床表现、分布模式和预后。

胸椎管变异型肌萎缩侧索硬化症(T-ALS)是一种罕见的亚型,仅影响3%的肌萎缩侧索硬化症(ALS)患者。为了更好地理解这种变异,本文旨在描述T-ALS的典型特征,包括临床表现、分布模式和预后。

对59例T-ALS患者进行了回顾性图表分析,这些患者来自于2002年至2018年间乌尔姆大学医院(德国乌尔姆)神经内科的3549例ALS患者的临床数据库,包括2020年的死亡记录查询。纳入标准为根据经修订的El Escorial标准诊断为明确的ALS,胸肌无力为ALS的首发症状。对照组包括517名非胸椎型肌萎缩侧索硬化症(NT-ALS)患者,来自2010年至2018年间ALS登记处Swabia2的流行病学数据库,不包括原发性侧索硬化症以及家族/遗传形式本文发表在《神经病学,神经外科学和精神病学杂志》上(

比较了两个队列的临床参数,包括性别、发病年龄、诊断延迟、生存期(从症状开始到死亡的时间)、体重、使用无创通气(NIV)和有创通气(IV)以及传播模式。发病定义为首次轻瘫的发生。对于临床参数的描述,酌情使用绝对和相对频率或中位数和IQR。分类变量比较采用皮尔逊χ2检验。对于连续参数,采用Mann-Whitney U检验。生存率采用Kaplan-Meier法和对数秩检验进行分析。所有统计检验均在α=0.05的双侧显著性水平下进行。

2002年至2018年间,在乌尔姆大学医院(德国乌尔姆)神经内科治疗的3549例ALS患者中,59例(1.7%)患有T-ALS。与NT-ALS相比,T-ALS中的男性占比大(T-ALS:79.7%vs-NT-ALS:55.3%,p<0.001),与NT-ALS中的1.2:1.0相比,T-ALS中的男性:女性比例为3.9:1.0。T-ALS患者的中位发病年龄为65.4岁(IQR 58.7-71.2),T-ALS患者的中位发病年龄为67.8岁(IQR 58.2-74.4)(p=0.08)。在女性患者中,T-ALS的发病年龄比NT-ALS的年轻(T-ALS:60.5岁(IQR 48.8-65.3),而NT-ALS:69.1岁(IQR 59.2-74.7),p=0.004)。

临床结果统计

根据临床表现,我们确定了两个不同的T-ALS亚组,其特征为呼吸肌(n=37)或椎旁肌(n=22)变异。与NT-ALS相比,T-ALS的中位诊断延迟更长(11个月(IQR 6-18)与6个月(IQR 3-11),p<0.001)。T-ALS患者的中位生存期为34个月(95%) CI 28.5至29.5),而25个月(95% NT-ALS(在线补充图1)中的CI 23.0至27.0,p=0.01)。在T-ALS队列中,观察到呼吸性发作和椎旁发作患者之间没有差异(呼吸性发作:中位生存期30个月,95% CI 17.0至42.1;椎旁病变:35.0,95% CI 28.8至41.2;p=0.60)。在T-ALS患者中,60.0%的患者在发病后12个月内开始NIV或IV治疗,而NT-ALS患者仅为7.2%(p<0.001)。

在3个月内,两组之间的体重减轻没有差异。在大多数T-ALS患者(n=32,54.2%)中,第二个受累区域是颈部。腰椎区其次为25.4%(n=15),延髓区为20.3%(n=12)。结果显示T-ALS在女性中很少见,与NT-ALS患者相比,T-ALS女性患者的发病年龄更早。考虑到胸椎发病的罕见性,预计T-ALS患者的诊断延迟会显著延长。
总之,与NT-ALS相比,T-ALS的主要特征是男性占优势、女性发病年龄较早、体重明显减轻、早期依赖机械通气,但生存期更长。

评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983198, encodeId=8c9819831989f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jan 28 06:43:15 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696004, encodeId=f7851696004cf, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Mon Aug 29 12:43:15 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342914, encodeId=1a151342914b2, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489990, encodeId=366b148999032, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503181, encodeId=d7c41503181ec, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523477, encodeId=00eb15234e773, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062922, encodeId=33531062922ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01c5209406, createdName=14757fdfm46暂无昵称, createdTime=Fri Oct 22 13:44:22 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062906, encodeId=83701062906f7, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Oct 22 12:41:16 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2022-01-28 30397604
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983198, encodeId=8c9819831989f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jan 28 06:43:15 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696004, encodeId=f7851696004cf, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Mon Aug 29 12:43:15 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342914, encodeId=1a151342914b2, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489990, encodeId=366b148999032, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503181, encodeId=d7c41503181ec, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523477, encodeId=00eb15234e773, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062922, encodeId=33531062922ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01c5209406, createdName=14757fdfm46暂无昵称, createdTime=Fri Oct 22 13:44:22 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062906, encodeId=83701062906f7, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Oct 22 12:41:16 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2022-08-29 chendoc252

    #萎缩#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1983198, encodeId=8c9819831989f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jan 28 06:43:15 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696004, encodeId=f7851696004cf, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Mon Aug 29 12:43:15 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342914, encodeId=1a151342914b2, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489990, encodeId=366b148999032, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503181, encodeId=d7c41503181ec, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523477, encodeId=00eb15234e773, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062922, encodeId=33531062922ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01c5209406, createdName=14757fdfm46暂无昵称, createdTime=Fri Oct 22 13:44:22 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062906, encodeId=83701062906f7, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Oct 22 12:41:16 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1983198, encodeId=8c9819831989f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jan 28 06:43:15 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696004, encodeId=f7851696004cf, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Mon Aug 29 12:43:15 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342914, encodeId=1a151342914b2, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489990, encodeId=366b148999032, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503181, encodeId=d7c41503181ec, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523477, encodeId=00eb15234e773, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062922, encodeId=33531062922ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01c5209406, createdName=14757fdfm46暂无昵称, createdTime=Fri Oct 22 13:44:22 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062906, encodeId=83701062906f7, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Oct 22 12:41:16 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-10-23 yyj065

    #胸椎#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1983198, encodeId=8c9819831989f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jan 28 06:43:15 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696004, encodeId=f7851696004cf, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Mon Aug 29 12:43:15 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342914, encodeId=1a151342914b2, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489990, encodeId=366b148999032, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503181, encodeId=d7c41503181ec, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523477, encodeId=00eb15234e773, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062922, encodeId=33531062922ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01c5209406, createdName=14757fdfm46暂无昵称, createdTime=Fri Oct 22 13:44:22 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062906, encodeId=83701062906f7, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Oct 22 12:41:16 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-10-23 neizongke
  6. [GetPortalCommentsPageByObjectIdResponse(id=1983198, encodeId=8c9819831989f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jan 28 06:43:15 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696004, encodeId=f7851696004cf, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Mon Aug 29 12:43:15 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342914, encodeId=1a151342914b2, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489990, encodeId=366b148999032, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503181, encodeId=d7c41503181ec, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523477, encodeId=00eb15234e773, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062922, encodeId=33531062922ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01c5209406, createdName=14757fdfm46暂无昵称, createdTime=Fri Oct 22 13:44:22 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062906, encodeId=83701062906f7, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Oct 22 12:41:16 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1983198, encodeId=8c9819831989f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jan 28 06:43:15 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696004, encodeId=f7851696004cf, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Mon Aug 29 12:43:15 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342914, encodeId=1a151342914b2, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489990, encodeId=366b148999032, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503181, encodeId=d7c41503181ec, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523477, encodeId=00eb15234e773, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062922, encodeId=33531062922ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01c5209406, createdName=14757fdfm46暂无昵称, createdTime=Fri Oct 22 13:44:22 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062906, encodeId=83701062906f7, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Oct 22 12:41:16 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-10-22 14757fdfm46暂无昵称

    谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1983198, encodeId=8c9819831989f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jan 28 06:43:15 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696004, encodeId=f7851696004cf, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Mon Aug 29 12:43:15 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342914, encodeId=1a151342914b2, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489990, encodeId=366b148999032, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503181, encodeId=d7c41503181ec, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523477, encodeId=00eb15234e773, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Sat Oct 23 13:43:15 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062922, encodeId=33531062922ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01c5209406, createdName=14757fdfm46暂无昵称, createdTime=Fri Oct 22 13:44:22 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062906, encodeId=83701062906f7, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Oct 22 12:41:16 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-10-22 yangchou

    好文章,谢谢分享。

    0

相关资讯

JNNP:低代谢状态:肌萎缩侧索硬化预后较好的预测因子

研究的目的是在ALS患者转诊队列中评估低代谢状态与正常代谢和高代谢状态的患病率,并将其与临床表型、进化率和生存率相关联。

Lancet子刊:世界五大绝症之一“渐冻人”患者新药治疗的有效性研究

ALS是一种与运动神经元相关的进行性神经变性疾病,

JNNP:尿N末端肌联蛋白片段与尿肌酐的比率是肌萎缩性侧索硬化症的新生物标志物

肌萎缩侧索硬化症(ALS)是一种神经退行性疾病,其特征是上下运动神经元迅速丧失,在发病后平均3-4年内导致瘫痪和死亡。大多数ALS病例为散发性,病因不明。在对150多种不同的治疗药物或策略进行了半个多

Nature子刊重磅研究:告别腰穿!血液检测神经丝光链辅助诊断神经退行性疾病

血液检测神经丝光链水平可以准确地表明有认知问题的人存在潜在的神经变性,如唐氏综合症痴呆症、运动神经元病(ALS)和额颞叶痴呆症。

JNNP:GBA基因变异影响肌萎缩侧索硬化症患者的认知状态

肌萎缩侧索硬化症(ALS)是一种持续进行的上下运动神经元变性疾病。

JNNP:较高的血液高密度脂蛋白和载脂蛋白A1水平与肌萎缩侧索硬化风险降低相关

除了占不到15%病例的少数单基因变异外,神经退行性疾病肌萎缩侧索硬化症(ALS)发展的确切因素尚不清楚。目前主要理论有:神经毒性物质累积;自由基使神经细胞膜受损;神经生长因子缺乏,使神经细胞无法持续生

拓展阅读

《JAMA Neurology》:Reldesemtiv在肌萎缩侧索硬化症中的作用:来自COURAGE-ALS随机临床试验的结果

COURAGE-ALS试验提供了重要的科学证据,帮助指导未来ALS治疗策略的发展方向,并提醒研究人员在推进潜在疗法时需考虑更多因素以提高成功率。

肌萎缩侧索硬化症当前潜在的发病机制

通过对ALS发病机制的研究,可以为寻找有效的治疗方法提供新的证据和线索。

《Neurological Sciences》:阿利莫氯莫治疗肌萎缩侧索硬化症的安全性和有效性

虽然阿利莫氯莫在ALS治疗中显示出一定的潜力,但现有证据不足以证明其具有显著疗效。

《Mol Neurobiol》:肌萎缩侧索硬化症和帕金森病:脑组织转录组分析揭示相互作用

这项研究通过对ALS和PD患者脑组织转录组的深入分析,揭示了两种疾病间潜在的分子交互作用,为进一步探索新型治疗方法奠定了基础。

Med:免疫系统失调或是肌萎缩侧索硬化症进展 “幕后推手”

本研究揭示了免疫标记物的失调与疾病进展之间的密切联系。研究发现,ALS患者的免疫系统表现出更高的变异性,而快速进展的患者则表现出更低的变异性,但免疫标记物的失调更为一致。

《Lancet neurology》:基因重复扩增引起的肌萎缩侧索硬化症——从遗传学到治疗学

对于携带者而言,血样中大约100个重复但在脑中有数千个重复的情况并不罕见。这也提示我们关于脑部镶嵌现象的存在可能性,即只有一部分脑细胞含有更长的重复序列。